Treatment of recurrent small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 2, 2004, Pages 387-416

  Davies, Angela M ^a   Evans, William K ^b,c   MacKay, Jean A ^d   Shepherd, Frances A ^c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIINFECTIVE AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETHYLNITROSOUREA; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LONIDAMINE; MELAMINE; NARCICLASINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TENIPOSIDE; TOPOTECAN; VINCRISTINE; VINDESINE;

ANEMIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; FEVER; HEART FAILURE; HUMAN; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LUNG SMALL CELL CANCER; LUNG TOXICITY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 1942439151     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2003.12.010     Document Type: Review

References (69)

1. Page N., Read W., Tierney R., Arquette M., Piccirillo J., Govindan R. The epidemiology of small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 21:2002;305a.
2. Clark R., Ihde D.C. Small-cell lung cancer: treatment progress and prospects. Oncology (Huntingt). 12(5):1998;647-658.
3. Giaccone G., Donadio M., Bonardi G., Testore F., Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 6(8):1988;1264-1270.
4. Johnson D.H., Greco F.A., Strupp J., Hande K.R., Hainsworth J.D. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 8(10):1990;1613-1617.
5. Ebi N., Kubota K., Nishiwaki Y., Hojo F., Matsumoto T., Kakinuma R.et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol. 27(3):1997;166-169.
6. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P.et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 15(5):1997;2090-2096.
7. Hainsworth J.D., Burris H.A. III, Erland J.B., Baker M., Scullin D.C. Jr., Shaffer D.W.et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 21(2):2003;193-199.
8. Sandler A.B. Irinotecan in small-cell lung cancer: the US experience. Oncology (Huntingt). 15(1 Suppl 1):2001;11-12.
9. Sonpavde G., Ansari R., Walker P., Sciortino D.F., Gabrys G.T., Murdock A.et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol. 23(1):2000;68-70.
10. Masters G., Declerck L., Blanke C., Sandler A., DeVore R., Miller K.et al. Gemcitabine in refractory or relapsed small cell lung cancer (SCLC) - E1597: an ECOG phase II trial [abstract]. Proc Am Soc Clin Oncol. 19:2000;527a. Abstract 2070.
11. Ando M., Kobayashi K., Yoshioka H., Hasegawa K., Seike M., Gemma A.et al. Weekly administration of irinotecan (CPT-11) plus cisplatin (CDDP) for refractory or relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 20:2001;319a. Abstract 1273.
12. Kosmas C., Tsavaris N.B., Malamos N.A., Vadiaka M., Koufos C. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol. 19(1):2001;119-126.
13. Domine M., Gonzalez Larriba J., Garcia Gomez R., Morales S., Isla D., Garcia Giron C.et al. Paclitaxel and gemcitabine for refractory or relapsed small cell lung cancer (SCLC): a multicentric phase II study [abstract]. Eur J Cancer. 37(Suppl 6):2001;62. Abstract 220.
14. Ardizzoni A., Manegold C., Gaafar R., Buchholdz E., Debruyne C., Damen S.et al. Combination chemotherapy with cisplatin and topotecan as second line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): an EORTC LCCG phase II study [absttract]. Proc Am Soc Clin Oncol. 18:1999;471a. Abstract 1871.
15. Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S.et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 10(8):1992;1225-1229.
16. von Pawel J., Depierre A., Hans K., Moro D., Clark P., Gatzemeier U.et al. Topotecan (hycamtin) in small cell lung cancer (SCLC) after failure of first-line therapy: a multicentre phase II study [abstract]. Eur J Cancer. 33(Suppl 8):1997;229. Abstract 1038.
17. Jassem J., Karnicka-Mlodkowska H., van Pottelsberghe C., van Glabbeke M., Noseda M.A., Ardizzoni A.et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer. 29A(12):1993;1720-1722.
18. Lake D., Johnson E., Herndon J., Green M. Phase II trial of Navelbine (NVB) in relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 16:1997;473a. Abstract 1703.
19. van der Lee I., Smit E.F., van Putten J.W., Groen H.J., Schlosser N.J., Postmus P.E.et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 12(4):2001;557-561.
20. Perez-Soler R., Glisson B.S., Lee J.S., Fossella F.V., Murphy W.K., Shin D.M.et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 14(10):1996;2785-2790.
21. Fujita A., Takabatake H., Tagaki S., Sekine K. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology. 59(2):2000;105-109.
22. Kubota K., Nishiwaki Y., Kakinuma R., Hojo F., Matsumoto T., Ohmatsu H.et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol. 15(1):1997;292-296.
23. Faylona E.A., Loehrer P.J., Ansari R., Sandler A.B., Gonin R., Einhorn L.H. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol. 13(5):1995;1209-1214.
24. Johnson E., Lake D., Herndon J., Green M. Phase II trial of navelbine (NVB) plus doxorubicin (DOX) in relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 16:1997;471a. abstract 1696.
25. Okishio K., Furuse K., Kawahara M., Ogawara M., Atagi S., Kawaguchi T.et al. A phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 17:1998;. abstract 1914.
26. Graziano S.L., Lee K., Propert K.J., Tinsley R., Hayes D.M., Green M.et al. Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study. Med Pediatr Oncol. 18(1):1990;22-26.
27. Batist G., Carney D.N., Cowan K.H., Veach S.R., Gilliom M., Bunn P.A.et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 4(6):1986;982-986.
28. Porter L.L. III, Johnson D.H., Hainsworth J.D., Hande K.R., Greco F.A. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep. 69(5):1985;479-481.
29. Kakolyris S., Mavroudis D., Tsavaris N., Souglakos J., Tsiafaki P., Kalbakis K.et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol. 12(2):2001;193-197.
30. Falk S.J., Maughan T.S., Laurence V.M., Lamont A., Boote D., Ford J.M.et al. Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer. Clin Oncol (R Coll Radiol). 5(2):1993;85-88.
31. Remick S.C., Neville A.J., Willson J.K. Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung. Cancer Treat Rep. 71(6):1987;575-580.
32. Sprandio J., Langer C., Lusch C., Rausch G., Kosierowski R., Fox S.et al. Phase II study of daily oral etoposide and hexamethylmelamine (altretamine) in relapsed small cell lung carcinoma (SCLC) [abstract 1845]. Proc Am Soc Clin Oncol. 18:1999.
33. Figoli F., Veronesi A., Ardizzoni A., Canobbio L., Bruschi G., Mazza F.et al. Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. Cancer Invest. 6(1):1988;1-5.
34. Evans W.K., Osoba D., Feld R., Shepherd F.A., Bazos M.J., DeBoer G. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol. 3(1):1985;65-71.
35. Lopez J.A., Mann J., Grapski R.T., Nassif E., Vannicola P., Krikorian J.G.et al. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep. 69(4):1985;369-371.
36. Albain K.S., Crowley J.J., Hutchins L., Gandara D., O'Bryan R.M., von Hoff D.D.et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer. 72(4):1993;1184-1191.
37. O'Bryan R.M., Crowley J.J., Kim P.N., Epstein R.B., Neilan B., Coltman C.A. Jret al. Comparison of etoposide and cisplatin with bis-chloro- ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer. 65(4):1990;856-860.
38. von Pawel J., Gatzemeier U., Pujol J.L., Moreau L., Bildat S., Ranson M.et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 19(6):2001;1743-1749.
39. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G.et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 17(2):1999;658-667.
40. Eckardt J.R., von Pawel J., Hainsworth J.D., Corso S., Rinaldi D., Preston A.et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study. Proc Am Soc Clin Oncol. 22:2003;. abstract 2488.
41. Sculier J.P., Lafitte J.J., Lecomte J., Berghmans T., Thiriaux J., Van Cutsem O.et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol. 13(9):2002;1454-1459.
42. Vincent M., Evans B., Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol. 21(1):1988;45-48.
43. Postmus P.E., Berendsen H.H., van Zandwijk N., Splinter T.A., Burghouts J.T., Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 23(9):1987;1409-1411.
44. Le Chevalier T., Ibrahim P., Chomy P., Riviere A., Monnier A., Magherini E.et al. A phase II study of irinotecan (CPT-11) in patients with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy [abstract]. Proc Am Soc Clin Oncol. 16:1997;450a. Abstract 1617.
45. Fernandez-Rodrigues R., Ferreiro J., Rubio I., Abon G., Fuente N., Mane J.M.et al. Topotecan (TPT) as second-line treatment in small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 20:2001;283b. Abstract 2883.
46. Huber R., Gatzemeier U., Gosse H., von Pawel J., Hruska D., Mezger J.et al. Topotecan in second line treatment of small cell lung cancer - reduced toxicity with individualized therapy. Proc Am Soc Clin Oncol. 19:2000;. abstract 2153.
47. Nishiwaki Y., Negoro S., Watanabe K., Fukuoka M., Niitani H. Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC) [abstract]. Eur J Cancer. 35(Suppl 4):1999;253.
48. Herben V.M.M., ten Bokkel Huinink W.W., Schot M., Hudson I., Beijnen J.H. Continuous infusion of low-dose topotecan (TOP): a clinical pharmacologic phase II study in patients with small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 16:1997;238a. Abstract 838.
49. Furuse K., Kubota K., Kawahara M., Takada M., Kimura I., Fujii M.et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology. 53(2):1996;169-172.
50. Einhorn L.H., Pennington K., McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol. 17(Suppl 2):1990;32-35.
51. Nakamura H., Azuma M., Miyagi K., Teruya M., Touyama M., Tohyama M.et al. A pilot study of docetaxel (TXT) as salvage chemotherapy in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 20:2001;. abstract 2872.
52. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 77(2):1998;347-351.
53. Masters G.A., Declerck L., Blanke C., Sandler A., DeVore R., Miller K.et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 21(8):2003;1550-1555.
54. Masuda N., Matsui K., Negoro S., Takifuji N., Takeda K., Yana T.et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 16(10):1998;3329-3334.
55. Groen H.J., Fokkema E., Biesma B., Kwa B., van Putten J.W., Postmus P.E.et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol. 17(3):1999;927-932.
56. Negoro S., Uejima H., Takeda K., Miyazaki M. A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small cell lung cancer (SCLC). Proc Ann Oncol. 11(Suppl 4):2000;109.
57. Samantas E., Kalofonos H., Linardou H., Nicolaides C., Mylonakis N., Fountzilas G.et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann Oncol. 11:2000;1395-1397.
58. Woll P.J., Basser R., Le Chevalier T., Drings P., Perez Manga G., Adenis A.et al. Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. Br J Cancer. 76:1997;264-265.
59. Stewart D.J., Dahrouge S., Soltys K.M., Evans W.K. A phase II study of 5-fluorouracil plush high-dose folinic acid in the treatment of recurrent small cell lung cancer. Am J Clin Oncol. 18:1995;130-132.
60. Planting A.S., Splinter T.A., Ardizzoni A., Estape J., Giaccone G., Kirkpatrick A.et al. Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. Cancer Chemother Pharmacol. 29:1992;409-411.
61. Giaccone G., Donadio M., Bonardi G., Iberti V., Calciati A. 4′EPI-doxorubicin in advanced lung cancer. A phase II trial. Invest New Drugs. 8:1990;393-396.
62. Loehrer P.J. Sr., Birch R., Kramer B.S., Greco F.A., Einhorn L.H. Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 70:1986;919-920.
63. Postmus P.E., Smit E.F., Berendsen H.H., Haazma-Reiche H. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Semin Oncol. 19:1992;17-23.
64. Smit E.F., Berendsen H.H., de Vries E.G., Mulder N.H., Postmus P.E. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 25:1989;202-204.
65. Chiuten D.F., Carr D.T., Dhingra H.M., Murphy W.K., Spitzer G., Umsawasdi T.et al. Combination chemotherapy with vindesine and cisplatin for refractory small cell bronchogenic carcinoma. Cancer Treat Rep. 70:1986;795-796.
66. Gridelli C., De Marinis F., Rossi A., Tucci E., D'Aprile M., Cioffi R.et al. A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancer. Anticancer Res. 17:1997;1277-1279.
67. Postmus P.E., Smit E.F., Kirkpatrick A., Splinter T.A. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 29:1993;204-207.
68. Frytak S., Eagan R.T., Richardson R.L., Creagan E.T., Jett J.L., Coles D.T.et al. Cyclophosphamide, etoposide, and infusion cisplatin in refractory small cell lung cancer. A preliminary report. Am J Clin Oncol. 10:1987;33-35.
69. Lebeau B., Giraud F., Baud M. Oral chemotherapy by Lomustine-Etoposide- Cyclophosphamide for recurrent small cell lung cancer (SCLC). ASCO abstracts. 20:2001;281b.